Compare CLRO & CRIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLRO | CRIS |
|---|---|---|
| Founded | 1983 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.4M | 14.0M |
| IPO Year | 2018 | 2000 |
| Metric | CLRO | CRIS |
|---|---|---|
| Price | $3.14 | $0.49 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $17.00 |
| AVG Volume (30 Days) | 3.9K | ★ 286.7K |
| Earning Date | 05-18-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 91.57 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $46,067,000.00 | $9,898,000.00 |
| Revenue This Year | N/A | $27.10 |
| Revenue Next Year | N/A | $67.74 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 11.59 | ★ 31.50 |
| 52 Week Low | $0.29 | $0.46 |
| 52 Week High | $15.42 | $3.13 |
| Indicator | CLRO | CRIS |
|---|---|---|
| Relative Strength Index (RSI) | 43.28 | 34.97 |
| Support Level | $2.71 | N/A |
| Resistance Level | $3.89 | $0.63 |
| Average True Range (ATR) | 0.27 | 0.04 |
| MACD | 0.03 | -0.00 |
| Stochastic Oscillator | 7.53 | 13.48 |
ClearOne Inc is a communications solutions company, which is engaged in designing, developing, and selling conferencing, collaboration, streaming, and digital signage solutions for audio, video, and visual communication. It sells its commercial products to end-users predominantly through a network of independent distributors, who in turn sell its products to dealers, systems integrators, and other resellers. Its products include DSP mixers, amplifiers, Video walls, professional cameras, and professional microphones among others. Geographically the firm has its business presence across the United States and international markets.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.